Literature DB >> 26806385

Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals.

Ramon Casanova1, Sudhir Varma2, Brittany Simpson3, Min Kim4, Yang An5, Santiago Saldana1, Carlos Riveros6, Pablo Moscato6, Michael Griswold7, Denise Sonntag8, Judith Wahrheit8, Kristaps Klavins8, Palmi V Jonsson9, Gudny Eiriksdottir10, Thor Aspelund11, Lenore J Launer12, Vilmundur Gudnason11, Cristina Legido Quigley4, Madhav Thambisetty13.   

Abstract

INTRODUCTION: Recently, quantitative metabolomics identified a panel of 10 plasma lipids that were highly predictive of conversion to Alzheimer's disease (AD) in cognitively normal older individuals (n = 28, area under the curve [AUC] = 0.92, sensitivity/specificity of 90%/90%).
METHODS: Quantitative targeted metabolomics in serum using an identical method as in the index study.
RESULTS: We failed to replicate these findings in a substantially larger study from two independent cohorts-the Baltimore Longitudinal Study of Aging ([BLSA], n = 93, AUC = 0.642, sensitivity/specificity of 51.6%/65.7%) and the Age, Gene/Environment Susceptibility-Reykjavik Study ([AGES-RS], n = 100, AUC = 0.395, sensitivity/specificity of 47.0%/36.0%). In analyses applying machine learning methods to all 187 metabolite concentrations assayed, we find a modest signal in the BLSA with distinct metabolites associated with the preclinical and symptomatic stages of AD, whereas the same methods gave poor classification accuracies in the AGES-RS samples. DISCUSSION: We believe that ours is the largest blood biomarker study of preclinical AD to date. These findings underscore the importance of large-scale independent validation of index findings from biomarker studies with relatively small sample sizes. Published by Elsevier Inc.

Entities:  

Keywords:  Biomarker; Machine learning; Metabolomics; Phospholipids; Preclinical Alzheimer's disease

Mesh:

Substances:

Year:  2016        PMID: 26806385      PMCID: PMC4947451          DOI: 10.1016/j.jalz.2015.12.008

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  25 in total

Review 1.  Translating biomarkers to clinical practice.

Authors:  R H Perlis
Journal:  Mol Psychiatry       Date:  2011-06-28       Impact factor: 15.992

2.  Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology.

Authors:  Yoshiaki Sato; Ikumi Suzuki; Tatsuji Nakamura; Francois Bernier; Ken Aoshima; Yoshiya Oda
Journal:  J Lipid Res       Date:  2011-12-27       Impact factor: 5.922

3.  Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics.

Authors:  Tamara B Harris; Lenore J Launer; Gudny Eiriksdottir; Olafur Kjartansson; Palmi V Jonsson; Gunnar Sigurdsson; Gudmundur Thorgeirsson; Thor Aspelund; Melissa E Garcia; Mary Frances Cotch; Howard J Hoffman; Vilmundur Gudnason
Journal:  Am J Epidemiol       Date:  2007-03-10       Impact factor: 4.897

4.  Quantitative and wide-ranging profiling of phospholipids in human plasma by two-dimensional liquid chromatography/mass spectrometry.

Authors:  Yoshiaki Sato; Tatsuji Nakamura; Ken Aoshima; Yoshiya Oda
Journal:  Anal Chem       Date:  2010-11-09       Impact factor: 6.986

5.  A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease.

Authors:  Nicola Greenberg; Antonio Grassano; Madhav Thambisetty; Simon Lovestone; Cristina Legido-Quigley
Journal:  Electrophoresis       Date:  2009-04       Impact factor: 3.535

6.  Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics.

Authors:  Xianlin Han; Steve Rozen; Stephen H Boyle; Caroline Hellegers; Hua Cheng; James R Burke; Kathleen A Welsh-Bohmer; P Murali Doraiswamy; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

7.  Differences between human plasma and serum metabolite profiles.

Authors:  Zhonghao Yu; Gabi Kastenmüller; Ying He; Petra Belcredi; Gabriele Möller; Cornelia Prehn; Joaquim Mendes; Simone Wahl; Werner Roemisch-Margl; Uta Ceglarek; Alexey Polonikov; Norbert Dahmen; Holger Prokisch; Lu Xie; Yixue Li; H-Erich Wichmann; Annette Peters; Florian Kronenberg; Karsten Suhre; Jerzy Adamski; Thomas Illig; Rui Wang-Sattler
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

8.  Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.

Authors:  Eugenia Trushina; Tumpa Dutta; Xuan-Mai T Persson; Michelle M Mielke; Ronald C Petersen
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

9.  Metabolome in progression to Alzheimer's disease.

Authors:  M Orešič; T Hyötyläinen; S-K Herukka; M Sysi-Aho; I Mattila; T Seppänan-Laakso; V Julkunen; P V Gopalacharyulu; M Hallikainen; J Koikkalainen; M Kivipelto; S Helisalmi; J Lötjönen; H Soininen
Journal:  Transl Psychiatry       Date:  2011-12-13       Impact factor: 6.222

10.  Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples.

Authors:  Michaela Breier; Simone Wahl; Cornelia Prehn; Marina Fugmann; Uta Ferrari; Michaela Weise; Friederike Banning; Jochen Seissler; Harald Grallert; Jerzy Adamski; Andreas Lechner
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

View more
  61 in total

Review 1.  Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be "extraordinarily diverse".

Authors:  Madhav Thambisetty
Journal:  Am J Physiol Cell Physiol       Date:  2017-06-14       Impact factor: 4.249

2.  Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway.

Authors:  V R Varma; S Varma; Y An; T J Hohman; S Seddighi; R Casanova; A Beri; E B Dammer; N T Seyfried; O Pletnikova; A Moghekar; M R Wilson; J J Lah; R J O'Brien; A I Levey; J C Troncoso; M S Albert; M Thambisetty
Journal:  Mol Psychiatry       Date:  2016-11-22       Impact factor: 15.992

3.  Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.

Authors:  Sid E O'Bryant; Michelle M Mielke; Robert A Rissman; Simone Lista; Hugo Vanderstichele; Henrik Zetterberg; Piotr Lewczuk; Holly Posner; James Hall; Leigh Johnson; Yiu-Lian Fong; Johan Luthman; Andreas Jeromin; Richard Batrla-Utermann; Alcibiades Villarreal; Gabrielle Britton; Peter J Snyder; Kim Henriksen; Paula Grammas; Veer Gupta; Ralph Martins; Harald Hampel
Journal:  Alzheimers Dement       Date:  2016-11-18       Impact factor: 21.566

4.  Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging.

Authors:  Danni Li; Clinton Hagen; Ashely R Fett; Hai H Bui; David Knopman; Prashanthi Vemuri; Mary M Machulda; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  Neurobiol Aging       Date:  2019-03-18       Impact factor: 4.673

Review 5.  Nutrition and Metabolic Profiles in the Natural History of Dementia: Recent Insights from Systems Biology and Life Course Epidemiology.

Authors:  Sophie Lefèvre-Arbogast; Maude Wagner; Cécile Proust-Lima; Cécilia Samieri
Journal:  Curr Nutr Rep       Date:  2019-09

6.  Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease.

Authors:  Richard D Semba
Journal:  Adv Nutr       Date:  2020-07-01       Impact factor: 8.701

Review 7.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

8.  Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis.

Authors:  Zhiguang Huo; Lei Yu; Jingyun Yang; Yun Zhu; David A Bennett; Jinying Zhao
Journal:  Neurobiol Aging       Date:  2019-11-05       Impact factor: 4.673

9.  Biological sex and DNA repair deficiency drive Alzheimer's disease via systemic metabolic remodeling and brain mitochondrial dysfunction.

Authors:  Tyler G Demarest; Vijay R Varma; Darlene Estrada; Mansi Babbar; Sambuddha Basu; Uma V Mahajan; Ruin Moaddel; Deborah L Croteau; Madhav Thambisetty; Mark P Mattson; Vilhelm A Bohr
Journal:  Acta Neuropathol       Date:  2020-04-24       Impact factor: 17.088

Review 10.  A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations.

Authors:  Steven J Kiddle; Nicola Voyle; Richard J B Dobson
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.